{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:28:56Z","timestamp":1789183736694,"version":"build-2803163510"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lung cancer is the most common cancer in men and women. This cancer is divided into two main types, namely non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Around 85 to 90 percent of lung cancers\u00a0are NSCLC.\u00a0Repositioning potent candidate drugs in NSCLC treatment is one of the important topics in cancer studies. Drug repositioning (DR) or drug repurposing is a method for identifying new therapeutic uses of existing drugs. The current study applies a computational drug repositioning method to identify candidate drugs to treat NSCLC patients. To this end, at first, the transcriptomics profile of NSCLC and healthy (control) samples was obtained from the GEO database with the accession number GSE21933. Then, the gene co-expression network was reconstructed for NSCLC samples using the WGCNA, and two significant purple and magenta gene modules were extracted. Next, a list of transcription factor genes that regulate <jats:italic>purple<\/jats:italic> and <jats:italic>magenta<\/jats:italic> modules' genes was extracted from the TRRUST V2.0 online database, and the TF\u2013TG (transcription factors\u2013target genes) network was drawn. Afterward, a list of drugs targeting TF\u2013TG genes was obtained from the DGIdb V4.0 database, and two drug\u2013gene interaction networks, including drug-TG and drug-TF, were drawn. After analyzing gene co-expression TF\u2013TG, and drug\u2013gene interaction networks, 16 drugs were selected as potent candidates for NSCLC treatment. Out of 16 selected drugs, nine drugs, namely <jats:italic>Methotrexate, Olanzapine, Haloperidol, Fluorouracil, Nifedipine, Paclitaxel, Verapamil, Dexamethasone, and Docetaxel,<\/jats:italic> were chosen from the drug-TG sub-network. In addition, nine drugs, including <jats:italic>Cisplatin, Daunorubicin, Dexamethasone, Methotrexate, Hydrocortisone, Doxorubicin, Azacitidine<\/jats:italic><jats:italic>, <\/jats:italic><jats:italic>Vorinostat, and Doxorubicin Hydrochloride,<\/jats:italic> were selected from the drug-TF sub-network. <jats:italic>Methotrexate<\/jats:italic> and <jats:italic>Dexamethasone<\/jats:italic> are common in drug-TG and drug-TF sub-networks. In conclusion, this study proposed 16 drugs as potent candidates for NSCLC treatment through analyzing gene co-expression, TF\u2013TG, and drug\u2013gene interaction networks.<\/jats:p>","DOI":"10.1038\/s41598-022-13719-8","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T10:03:24Z","timestamp":1654682604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug\u2013gene interaction networks analysis"],"prefix":"10.1038","volume":"12","author":[{"given":"Habib","family":"MotieGhader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinaz","family":"Tabrizi-Nezhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid","family":"Deldar Abad Paskeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Baradaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahad","family":"Mokhtarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Lanjanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mehdi","family":"Jazayeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Khodadadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Nematzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Kiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazaher","family":"Maghsoudloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Masoudi-Nejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"key":"13719_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.mcna.2018.12.006","volume":"103","author":"F Nasim","year":"2019","unstructured":"Nasim, F., Sabath, B. F. & Eapen, G. A. Lung cancer. Med. Clin. N. Am. 103, 463\u2013473. https:\/\/doi.org\/10.1016\/j.mcna.2018.12.006 (2019).","journal-title":"Med. Clin. N. Am."},{"key":"13719_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc3775","volume":"14","author":"Z Chen","year":"2014","unstructured":"Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F. & Wong, K.-K. Non-small-cell lung cancers: A heterogeneous set of diseases. Nat. Rev. Cancer 14, 535\u2013546 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"13719_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3892\/or.2013.2631","volume":"30","author":"S Langhammer","year":"2013","unstructured":"Langhammer, S. Rationale for the design of an oncology trial using a generic targeted therapy multi-drug regimen for NSCLC patients without treatment options. Oncol. Rep. 30, 1535\u20131541 (2013).","journal-title":"Oncol. Rep."},{"key":"13719_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-019-2056-3","volume":"17","author":"X Gao","year":"2019","unstructured":"Gao, X. et al. Estrogen receptors promote NSCLC progression by modulating the membrane receptor signaling network: A systems biology perspective. J. Transl. Med. 17, 1\u201315 (2019).","journal-title":"J. Transl. Med."},{"key":"13719_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10863-021-09875-7","volume":"53","author":"M Zhao","year":"2021","unstructured":"Zhao, M., Li, X. & Chen, X. GOLM1 predicts poor prognosis of patients with NSCLC and is associated with the proliferation and chemo-sensitivity of cisplatin in NSCLC cells: Bioinformatics analysis and laboratory validation. J. Bioenerg. Biomembr. 53, 177\u2013189 (2021).","journal-title":"J. Bioenerg. Biomembr."},{"key":"13719_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43141-021-00134-1","volume":"19","author":"R Islam","year":"2021","unstructured":"Islam, R. et al. Identification of molecular biomarkers and pathways of NSCLC: Insights from a systems biomedicine perspective. J. Genet. Eng. Biotechnol. 19, 1\u20139 (2021).","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"13719_CR7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.21037\/atm-20-2430","volume":"9","author":"Y-Q Zhang","year":"2021","unstructured":"Zhang, Y.-Q. et al. Evaluation of the roles and regulatory mechanisms of PD-1 target molecules in NSCLC progression. Ann. Transl. Med. 9, 14 (2021).","journal-title":"Ann. Transl. Med."},{"key":"13719_CR8","doi-asserted-by":"publisher","first-page":"eabd5524","DOI":"10.1126\/scitranslmed.abd5524","volume":"13","author":"CG Begley","year":"2021","unstructured":"Begley, C. G. et al. Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. Sci. Transl. Med. 13, eabd5524 (2021).","journal-title":"Sci. Transl. Med."},{"key":"13719_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12896-021-00680-z","volume":"21","author":"M Adhami","year":"2021","unstructured":"Adhami, M., Sadeghi, B., Rezapour, A., Haghdoost, A. A. & MotieGhader, H. Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein\u2013protein interaction network analysis. BMC Biotechnol. 21, 1\u201311 (2021).","journal-title":"BMC Biotechnol."},{"key":"13719_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-01410-3","volume":"11","author":"H MotieGhader","year":"2021","unstructured":"MotieGhader, H., Safavi, E., Rezapour, A. & Amoodizaj, F. F. Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis. Sci. Rep. 11, 1\u201315 (2021).","journal-title":"Sci. Rep."},{"key":"13719_CR11","doi-asserted-by":"publisher","first-page":"1280237","DOI":"10.1155\/2021\/1280237","volume":"2021","author":"NS Soleimani Zakeri","year":"2021","unstructured":"Soleimani Zakeri, N. S., Pashazadeh, S. & MotieGhader, H. Drug repurposing for Alzheimer\u2019s disease based on protein\u2013protein interaction network. Biomed. Res. Int. 2021, 1280237. https:\/\/doi.org\/10.1155\/2021\/1280237 (2021).","journal-title":"Biomed. Res. Int."},{"key":"13719_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.compbiomed.2019.05.006","volume":"109","author":"Y Masoudi-Sobhanzadeh","year":"2019","unstructured":"Masoudi-Sobhanzadeh, Y., Omidi, Y., Amanlou, M. & Masoudi-Nejad, A. DrugR+: A comprehensive relational database for drug repurposing, combination therapy, and replacement therapy. Comput. Biol. Med. 109, 254\u2013262 (2019).","journal-title":"Comput. Biol. Med."},{"key":"13719_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: Progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"13719_CR14","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s11030-020-10144-9","volume":"25","author":"SA Hooshmand","year":"2021","unstructured":"Hooshmand, S. A. et al. A multimodal deep learning-based drug repurposing approach for treatment of COVID-19. Mol. Divers. 25, 1717\u20131730 (2021).","journal-title":"Mol. Divers."},{"key":"13719_CR15","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.7150\/ijbs.24612","volume":"14","author":"H Xue","year":"2018","unstructured":"Xue, H., Li, J., Xie, H. & Wang, Y. Review of drug repositioning approaches and resources. Int. J. Biol. Sci. 14, 1232 (2018).","journal-title":"Int. J. Biol. Sci."},{"key":"13719_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1155\/2021\/1280237","volume":"2021","author":"NS Soleimani Zakeri","year":"2021","unstructured":"Soleimani Zakeri, N. S., Pashazadeh, S. & MotieGhader, H. Drug repurposing for Alzheimer\u2019s disease based on protein-protein interaction network. BioMed Res. Int. 2021, 14 (2021).","journal-title":"BioMed Res. Int."},{"key":"13719_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2174\/15748936113086660013","volume":"9","author":"M Ghasemi","year":"2014","unstructured":"Ghasemi, M., Seidkhani, H., Tamimi, F., Rahgozar, M. & Masoudi-Nejad, A. Centrality measures in biological networks. Curr. Bioinform. 9, 426\u2013441 (2014).","journal-title":"Curr. Bioinform."},{"key":"13719_CR18","unstructured":"Moti Ghader, H., KeyKhosravi, D. & HosseinAliPour, A. Asian Conference on Intelligent Information and Database Systems. 247\u2013257 (Springer, 2021)."},{"key":"13719_CR19","doi-asserted-by":"publisher","first-page":"194416","DOI":"10.1016\/j.bbagrm.2019.194416","volume":"1863","author":"F Conte","year":"2020","unstructured":"Conte, F. et al. A paradigm shift in medicine: A comprehensive review of network-based approaches. Biochim. Biophys. BBA Acta Gene Regulat. Mech. 1863, 194416 (2020).","journal-title":"Biochim. Biophys. BBA Acta Gene Regulat. Mech."},{"key":"13719_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-44944-3","volume":"9","author":"M Kouhsar","year":"2019","unstructured":"Kouhsar, M., AzimzadehJamalkandi, S., Moeini, A. & Masoudi-Nejad, A. Detection of novel biomarkers for early detection of non-muscle-invasive bladder cancer using competing endogenous RNA network analysis. Sci. Rep. 9, 1\u201315 (2019).","journal-title":"Sci. Rep."},{"key":"13719_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1008686","volume":"17","author":"G Fiscon","year":"2021","unstructured":"Fiscon, G., Conte, F., Farina, L. & Paci, P. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. PLoS Comput. Biol. 17, e1008686 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"13719_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-021-04076-w","volume":"22","author":"G Fiscon","year":"2021","unstructured":"Fiscon, G. & Paci, P. SAveRUNNER: An R-based tool for drug repurposing. BMC Bioinform. 22, 1\u201310 (2021).","journal-title":"BMC Bioinform."},{"key":"13719_CR23","first-page":"5697","volume":"16","author":"X Li","year":"2018","unstructured":"Li, X., Li, B., Ran, P. & Wang, L. Identification of ceRNA network based on a RNA-seq shows prognostic lncRNA biomarkers in human lung adenocarcinoma. Oncol. Lett. 16, 5697\u20135708 (2018).","journal-title":"Oncol. Lett."},{"key":"13719_CR24","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1093\/bioinformatics\/bty133","volume":"34","author":"A Peyvandipour","year":"2018","unstructured":"Peyvandipour, A., Saberian, N., Shafi, A., Donato, M. & Draghici, S. A novel computational approach for drug repurposing using systems biology. Bioinformatics 34, 2817\u20132825 (2018).","journal-title":"Bioinformatics"},{"key":"13719_CR25","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1093\/nar\/gkaa1272","volume":"49","author":"W-F Guo","year":"2021","unstructured":"Guo, W.-F. et al. Network controllability-based algorithm to target personalized driver genes for discovering combinatorial drugs of individual patients. Nucleic Acids Res. 49, e37\u2013e37 (2021).","journal-title":"Nucleic Acids Res."},{"key":"13719_CR26","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1016\/j.csbj.2021.07.007","volume":"19","author":"A Li","year":"2021","unstructured":"Li, A., Huang, H.-T., Huang, H.-C. & Juan, H.-F. LncTx: A network-based method to repurpose drugs acting on the survival-related lncRNAs in lung cancer. Comput. Struct. Biotechnol. J. 19, 3990\u20134002 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"13719_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-09920-4","volume":"12","author":"Z Abedi","year":"2022","unstructured":"Abedi, Z., MotieGhader, H., Hosseini, S. S., Sheikh BeigGoharrizi, M. A. & Masoudi-Nejad, A. mRNA\u2013miRNA bipartite networks reconstruction in different tissues of bladder cancer based on gene co-expression network analysis. Sci. Rep. 12, 1\u201317 (2022).","journal-title":"Sci. Rep."},{"key":"13719_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.741326","volume":"11","author":"AS Jain","year":"2021","unstructured":"Jain, A. S. et al. Everything old is new again: Drug repurposing approach for non-small cell lung cancer targeting MAPK signaling pathway. Front. Oncol. 11, 741326. https:\/\/doi.org\/10.3389\/fonc.2021.741326 (2021).","journal-title":"Front. Oncol."},{"key":"13719_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2021.1970629","author":"MK Thirunavukkarasu","year":"2021","unstructured":"Thirunavukkarasu, M. K. & Karuppasamy, R. Drug repurposing combined with MM\/PBSA based validation strategies towards MEK inhibitors screening. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2021.1970629 (2021).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"13719_CR30","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/ph14111126","volume":"14","author":"JC Boulos","year":"2021","unstructured":"Boulos, J. C. et al. Repurposing of the ALK inhibitor crizotinib for acute leukemia and multiple myeloma cells. Pharmaceuticals 14, 1126 (2021).","journal-title":"Pharmaceuticals"},{"key":"13719_CR31","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1039\/C7MB00400A","volume":"13","author":"H Motieghader","year":"2017","unstructured":"Motieghader, H., Kouhsar, M., Najafi, A., Sadeghi, B. & Masoudi-Nejad, A. mRNA\u2013miRNA bipartite network reconstruction to predict prognostic module biomarkers in colorectal cancer stage differentiation. Mol. BioSyst. 13, 2168\u20132180 (2017).","journal-title":"Mol. BioSyst."},{"key":"13719_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ygeno.2012.11.005","volume":"101","author":"H Ahmadi","year":"2013","unstructured":"Ahmadi, H. et al. HomoTarget: A new algorithm for prediction of microRNA targets in Homo sapiens. Genomics 101, 94\u2013100 (2013).","journal-title":"Genomics"},{"key":"13719_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100297","volume":"26","author":"X-T Li","year":"2021","unstructured":"Li, X.-T. et al. Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer. Cancer Treat. Res. Commun. 26, 100297 (2021).","journal-title":"Cancer Treat. Res. Commun."},{"key":"13719_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/CBM-201605","volume":"30","author":"G Wang","year":"2021","unstructured":"Wang, G. et al. Study of the co-expression gene modules of non-small cell lung cancer metastases. Cancer Biomark. 30, 321\u2013329 (2021).","journal-title":"Cancer Biomark."},{"key":"13719_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder, P. & Horvath, S. WGCNA: An R package for weighted correlation network analysis. BMC Bioinform. 9, 1\u201313 (2008).","journal-title":"BMC Bioinform."},{"key":"13719_CR36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder, P. & Horvath, S. WGCNA: An R package for weighted correlation network analysis. BMC Bioinform. 9, 559. https:\/\/doi.org\/10.1186\/1471-2105-9-559 (2008).","journal-title":"BMC Bioinform."},{"key":"13719_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1049\/syb2.12038","volume":"16","author":"W Ren","year":"2021","unstructured":"Ren, W. et al. RYR2 mutation in non-small cell lung cancer prolongs survival via down-regulation of DKK1 and up-regulation of GS1-115G20. 1: A weighted gene Co-expression network analysis and risk prognostic models. IET Syst. Biol. 16, 43 (2021).","journal-title":"IET Syst. Biol."},{"key":"13719_CR38","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1080\/21655979.2021.1960764","volume":"12","author":"B Chen","year":"2021","unstructured":"Chen, B., Xie, X., Lan, F. & Liu, W. Identification of prognostic markers by weighted gene co-expression network analysis in non-small cell lung cancer. Bioengineered 12, 4924\u20134935 (2021).","journal-title":"Bioengineered"},{"key":"13719_CR39","first-page":"193","volume":"56","author":"B Ling","year":"2020","unstructured":"Ling, B. et al. Identification of prognostic markers of lung cancer through bioinformatics analysis and in vitro experiments. Int. J. Oncol. 56, 193\u2013205 (2020).","journal-title":"Int. J. Oncol."},{"key":"13719_CR40","doi-asserted-by":"publisher","first-page":"D380","DOI":"10.1093\/nar\/gkx1013","volume":"46","author":"H Han","year":"2018","unstructured":"Han, H. et al. TRRUST v2: An expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 46, D380\u2013D386 (2018).","journal-title":"Nucleic Acids Res."},{"key":"13719_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357 (2009).","journal-title":"Nat. Protoc."},{"key":"13719_CR42","doi-asserted-by":"publisher","first-page":"D1144","DOI":"10.1093\/nar\/gkaa1084","volume":"49","author":"SL Freshour","year":"2021","unstructured":"Freshour, S. L. et al. Integration of the drug\u2013gene interaction database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res. 49, D1144\u2013D1151 (2021).","journal-title":"Nucleic Acids Res."},{"key":"13719_CR43","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"13719_CR44","first-page":"D498","volume":"48","author":"B Jassal","year":"2020","unstructured":"Jassal, B. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 48, D498\u2013D503 (2020).","journal-title":"Nucleic Acids Res."},{"key":"13719_CR45","doi-asserted-by":"publisher","first-page":"D668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"DS Wishart","year":"2006","unstructured":"Wishart, D. S. et al. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668\u2013D672 (2006).","journal-title":"Nucleic Acids Res."},{"key":"13719_CR46","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3390\/molecules25081913","volume":"25","author":"LAC Rudnik","year":"2020","unstructured":"Rudnik, L. A. C. et al. Co-loaded curcumin and methotrexate nanocapsules enhance cytotoxicity against non-small-cell lung cancer cells. Molecules 25, 1913 (2020).","journal-title":"Molecules"},{"key":"13719_CR47","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.2147\/DDDT.S178569","volume":"12","author":"D Xu","year":"2018","unstructured":"Xu, D. et al. Evaluation of methotrexate-conjugated gadolinium (III) for cancer diagnosis and treatment. Drug Des. Dev. Ther. 12, 3301 (2018).","journal-title":"Drug Des. Dev. Ther."},{"key":"13719_CR48","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00432-011-1132-8","volume":"138","author":"L-Q Du","year":"2012","unstructured":"Du, L.-Q. et al. Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells. J. Cancer Res. Clin. Oncol. 138, 811\u2013818 (2012).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"13719_CR49","first-page":"762","volume":"19","author":"D Zhang","year":"2020","unstructured":"Zhang, D., Zhang, Y., Cai, Z., Tu, Y. & Hu, Z. Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR\/AKT and VEGF signal pathways. Exp. Ther. Med. 19, 762\u2013770 (2020).","journal-title":"Exp. Ther. Med."},{"key":"13719_CR50","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.fct.2018.05.025","volume":"119","author":"H Ge","year":"2018","unstructured":"Ge, H. et al. Dexamethasone alleviates pemetrexed-induced senescence in non-small-cell lung cancer. Food Chem. Toxicol. 119, 86\u201397 (2018).","journal-title":"Food Chem. Toxicol."},{"key":"13719_CR51","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2298\/MPNS0812571S","volume":"61","author":"T \u0160ar\u010dev","year":"2008","unstructured":"\u0160ar\u010dev, T., Se\u010den, N., Sabo, A. & Pova\u017ean, \u0110. Influence of dexamethasone on appetite and body weight in lung cancer patients. Med. Pregl. 61, 571\u2013575 (2008).","journal-title":"Med. Pregl."},{"key":"13719_CR52","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1053\/j.jvca.2016.01.004","volume":"30","author":"JP Cata","year":"2016","unstructured":"Cata, J. P. et al. Lack of association between dexamethasone and long-term survival after non-small cell lung cancer surgery. J. Cardiothorac. Vasc. Anesth. 30, 930\u2013935 (2016).","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"13719_CR53","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12013-014-0489-0","volume":"72","author":"X Wang","year":"2015","unstructured":"Wang, X., Wang, L., Wang, H. & Zhang, H. Effectiveness of olanzapine combined with ondansetron in prevention of chemotherapy-induced nausea and vomiting of non-small cell lung cancer. Cell Biochem. Biophys. 72, 471\u2013473 (2015).","journal-title":"Cell Biochem. Biophys."},{"key":"13719_CR54","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9, T. et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350, 2343\u20132351 (2004).","journal-title":"N. Engl. J. Med."},{"key":"13719_CR55","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335\u20132342 (2004).","journal-title":"N. Engl. J. Med."},{"key":"13719_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12272-017-0979-x","volume":"41","author":"Y Wei","year":"2018","unstructured":"Wei, Y., Yang, P., Cao, S. & Zhao, L. The combination of curcumin and 5-fluorouracil in cancer therapy. Arch. Pharmacal Res. 41, 1\u201313 (2018).","journal-title":"Arch. Pharmacal Res."},{"key":"13719_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113695","volume":"171","author":"B Chovancova","year":"2020","unstructured":"Chovancova, B. et al. Calcium signaling affects migration and proliferation differently in individual cancer cells due to nifedipine treatment. Biochem. Pharmacol. 171, 113695 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"13719_CR58","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.3892\/mmr.2017.6818","volume":"16","author":"T Zhao","year":"2017","unstructured":"Zhao, T., Guo, D., Gu, Y. & Ling, Y. Nifedipine stimulates proliferation and migration of different breast cancer cells by distinct pathways. Mol. Med. Rep. 16, 2259\u20132263 (2017).","journal-title":"Mol. Med. Rep."},{"key":"13719_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113649","volume":"9","author":"D-Q Guo","year":"2014","unstructured":"Guo, D.-Q., Zhang, H., Tan, S.-J. & Gu, Y.-C. Nifedipine promotes the proliferation and migration of breast cancer cells. PLoS ONE 9, e113649 (2014).","journal-title":"PLoS ONE"},{"key":"13719_CR60","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler, A. et al. Paclitaxel\u2013carboplatin alone or with bevacizumab for non\u2013small-cell lung cancer. N. Engl. J. Med. 355, 2542\u20132550 (2006).","journal-title":"N. Engl. J. Med."},{"key":"13719_CR61","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.resinv.2018.09.004","volume":"57","author":"A Mouri","year":"2019","unstructured":"Mouri, A. et al. Combination therapy with carboplatin and paclitaxel for small cell lung cancer. Respir. Investig. 57, 34\u201339 (2019).","journal-title":"Respir. Investig."},{"key":"13719_CR62","first-page":"6211","volume":"15","author":"D Ma","year":"2018","unstructured":"Ma, D. et al. Paclitaxel increases the sensitivity of lung cancer cells to lobaplatin via PI3K\/Akt pathway. Oncol. Lett. 15, 6211 (2018).","journal-title":"Oncol. Lett."},{"key":"13719_CR63","first-page":"27","volume":"29","author":"C Zhang","year":"2009","unstructured":"Zhang, C. et al. Effect of verapamil on the expression of EGFR and NM23 in A549 human lung cancer cells. Anticancer Res. 29, 27\u201332 (2009).","journal-title":"Anticancer Res."},{"key":"13719_CR64","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/bjc.1987.214","volume":"56","author":"S Merry","year":"1987","unstructured":"Merry, S., Courtney, E., Fetherston, C., Kaye, S. & Freshney, R. Circumvention of drug resistance in human non-small cell lung cancer in vitro by verapamil. Br. J. Cancer 56, 401\u2013405 (1987).","journal-title":"Br. J. Cancer"},{"key":"13719_CR65","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.canlet.2019.10.006","volume":"468","author":"Z Shen","year":"2020","unstructured":"Shen, Z., Zhou, L., Zhang, C. & Xu, J. Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel. Cancer Lett. 468, 88\u2013101 (2020).","journal-title":"Cancer Lett."},{"key":"13719_CR66","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3389\/fonc.2019.01398","volume":"9","author":"H-H Zhou","year":"2019","unstructured":"Zhou, H.-H. et al. Erastin reverses ABCB1-mediated docetaxel resistance in ovarian cancer. Front. Oncol. 9, 1398 (2019).","journal-title":"Front. Oncol."},{"key":"13719_CR67","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.3390\/molecules25112576","volume":"25","author":"M Prieto-Vila","year":"2020","unstructured":"Prieto-Vila, M. et al. Quercetin inhibits Lef1 and resensitizes docetaxel-resistant breast cancer cells. Molecules 25, 2576 (2020).","journal-title":"Molecules"},{"key":"13719_CR68","unstructured":"Lin, J. et al. (American Society of Clinical Oncology, 2020)."},{"key":"13719_CR69","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong, D. K. et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34\u201343 (2006).","journal-title":"N. Engl. J. Med."},{"key":"13719_CR70","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMoa003034","volume":"346","author":"K Noda","year":"2002","unstructured":"Noda, K. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346, 85\u201391 (2002).","journal-title":"N. Engl. J. Med."},{"key":"13719_CR71","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.bbamem.2017.01.034","volume":"1859","author":"AC Alves","year":"2017","unstructured":"Alves, A. C. et al. The daunorubicin interplay with mimetic model membranes of cancer cells: A biophysical interpretation. Biochim. Biophys. Acta Biomembr. 1859, 941\u2013948 (2017).","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"13719_CR72","doi-asserted-by":"publisher","first-page":"136","DOI":"10.18433\/J3P88Z","volume":"13","author":"J Guo","year":"2010","unstructured":"Guo, J. & Lu, W.-L. Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells. J. Pharm. Pharm. Sci. 13, 136\u2013151 (2010).","journal-title":"J. Pharm. Pharm. Sci."},{"key":"13719_CR73","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/gcc.20538","volume":"47","author":"L Antonova","year":"2008","unstructured":"Antonova, L. & Mueller, C. R. Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: A possible molecular link between stress and breast cancer. Genes Chromosom. Cancer 47, 341\u2013352 (2008).","journal-title":"Genes Chromosom. Cancer"},{"key":"13719_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108614","volume":"112","author":"Y Hong","year":"2019","unstructured":"Hong, Y. et al. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine. Biomed. Pharmacother. 112, 108614 (2019).","journal-title":"Biomed. Pharmacother."},{"key":"13719_CR75","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2147\/DDDT.S198003","volume":"13","author":"C Cao","year":"2019","unstructured":"Cao, C., Wang, Q. & Liu, Y. Lung cancer combination therapy: Doxorubicin and \u03b2-elemene co-loaded, pH-sensitive nanostructured lipid carriers. Drug Des. Dev. Ther. 13, 1087 (2019).","journal-title":"Drug Des. Dev. Ther."},{"key":"13719_CR76","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1634\/theoncologist.2018-0292","volume":"23","author":"V Gregorc","year":"2018","unstructured":"Gregorc, V. et al. NGR-hTNF and doxorubicin as second-line treatment of patients with small cell lung cancer. Oncologist 23, 1133 (2018).","journal-title":"Oncologist"},{"key":"13719_CR77","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.2147\/OTT.S136218","volume":"10","author":"Y Yang","year":"2017","unstructured":"Yang, Y., Yin, W., Wu, F. & Fan, J. Combination of azacitidine and trichostatin A decreased the tumorigenic potential of lung cancer cells. Onco. Targets. Ther. 10, 2993 (2017).","journal-title":"Onco. Targets. Ther."},{"key":"13719_CR78","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ijc.24759","volume":"126","author":"TK Owonikoko","year":"2010","unstructured":"Owonikoko, T. K. et al. Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells. Int. J. Cancer 126, 743\u2013755 (2010).","journal-title":"Int. J. Cancer"},{"key":"13719_CR79","first-page":"525","volume":"41","author":"SE Park","year":"2019","unstructured":"Park, S. E. et al. Vorinostat enhances gefitinib-induced cell death through reactive oxygen species-dependent cleavage of HSP90 and its clients in non-small cell lung cancer with the EGFR mutation. Oncol. Rep. 41, 525\u2013533 (2019).","journal-title":"Oncol. Rep."},{"key":"13719_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2888-7","volume":"16","author":"C-H Pan","year":"2016","unstructured":"Pan, C.-H. et al. Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells. BMC Cancer 16, 1\u201311 (2016).","journal-title":"BMC Cancer"},{"key":"13719_CR81","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1080\/10837450.2020.1823992","volume":"25","author":"G Ya\u015fayan","year":"2020","unstructured":"Ya\u015fayan, G., Mega Tiber, P., Orun, O. & Alar\u00e7in, E. Doxorubicin hydrochloride loaded nanotextured films as a novel drug delivery platform for ovarian cancer treatment. Pharm. Dev. Technol. 25, 1289\u20131301. https:\/\/doi.org\/10.1080\/10837450.2020.1823992 (2020).","journal-title":"Pharm. Dev. Technol."},{"key":"13719_CR82","doi-asserted-by":"publisher","first-page":"13431","DOI":"10.1111\/jcmm.15966","volume":"24","author":"B Xiao","year":"2020","unstructured":"Xiao, B. et al. Doxorubicin hydrochloride enhanced antitumour effect of CEA-regulated oncolytic virotherapy in live cancer cells and a mouse model. J. Cell Mol. Med. 24, 13431\u201313439. https:\/\/doi.org\/10.1111\/jcmm.15966 (2020).","journal-title":"J. Cell Mol. Med."},{"key":"13719_CR83","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1021\/acsomega.0c05350","volume":"6","author":"M Di Francesco","year":"2021","unstructured":"Di Francesco, M. et al. Doxorubicin hydrochloride-loaded nonionic surfactant vesicles to treat metastatic and non-metastatic breast cancer. ACS Omega 6, 2973\u20132989. https:\/\/doi.org\/10.1021\/acsomega.0c05350 (2021).","journal-title":"ACS Omega"},{"key":"13719_CR84","doi-asserted-by":"publisher","DOI":"10.7812\/tpp\/18.313","author":"GD Friedman","year":"2020","unstructured":"Friedman, G. D. et al. Haloperidol and prostate cancer prevention: More epidemiologic research needed. Perm J. https:\/\/doi.org\/10.7812\/tpp\/18.313 (2020).","journal-title":"Perm J."},{"key":"13719_CR85","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jama.2017.11468","volume":"318","author":"D Hui","year":"2017","unstructured":"Hui, D. et al. Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: A randomized clinical trial. JAMA 318, 1047\u20131056. https:\/\/doi.org\/10.1001\/jama.2017.11468 (2017).","journal-title":"JAMA"},{"key":"13719_CR86","first-page":"62","volume":"53","author":"LK Radha Krishna","year":"2012","unstructured":"Radha Krishna, L. K., Poulose, V. J. & Goh, C. The use of midazolam and haloperidol in cancer patients at the end of life. Singap. Med. J. 53, 62\u201366 (2012).","journal-title":"Singap. Med. J."},{"key":"13719_CR87","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029942","volume":"9","author":"JR Hardy","year":"2019","unstructured":"Hardy, J. R. et al. Methotrimeprazine versus haloperidol in palliative care patients with cancer-related nausea: A randomised, double-blind controlled trial. BMJ Open 9, e029942. https:\/\/doi.org\/10.1136\/bmjopen-2019-029942 (2019).","journal-title":"BMJ Open"},{"key":"13719_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-14-S18-S1","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 14, 1\u201314 (2013).","journal-title":"BMC Bioinform."},{"key":"13719_CR89","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.taap.2003.09.009","volume":"194","author":"MM Romero-Benitez","year":"2004","unstructured":"Romero-Benitez, M. M. et al. In vivo erythroid recovery following paclitaxel injury: Correlation between GATA-1, c-MYB, NF-E2, Epo receptor expressions, and apoptosis. Toxicol. Appl. Pharmacol. 194, 230\u2013238. https:\/\/doi.org\/10.1016\/j.taap.2003.09.009 (2004).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"13719_CR90","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/FPC.0b013e3283313296","volume":"19","author":"A Schuhmacher","year":"2009","unstructured":"Schuhmacher, A. et al. Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet. Genomics 19, 843\u2013851 (2009).","journal-title":"Pharmacogenet. Genomics"},{"key":"13719_CR91","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00296-005-0624-8","volume":"25","author":"T Kusabe","year":"2005","unstructured":"Kusabe, T. et al. The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin\/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes. Rheumatol. Int. 25, 625\u2013630. https:\/\/doi.org\/10.1007\/s00296-005-0624-8 (2005).","journal-title":"Rheumatol. Int."},{"key":"13719_CR92","doi-asserted-by":"publisher","first-page":"597888","DOI":"10.3389\/fgene.2020.597888","volume":"11","author":"G Shi","year":"2020","unstructured":"Shi, G., Shen, Z., Liu, Y. & Yin, W. Identifying biomarkers to predict the progression and prognosis of breast cancer by weighted gene co-expression network analysis. Front. Genet. 11, 597888\u2013597888. https:\/\/doi.org\/10.3389\/fgene.2020.597888 (2020).","journal-title":"Front. Genet."},{"key":"13719_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1001057","volume":"7","author":"P Langfelder","year":"2011","unstructured":"Langfelder, P., Luo, R., Oldham, M. C. & Horvath, S. Is my network module preserved and reproducible?. PLoS Comput. Biol. 7, e1001057 (2011).","journal-title":"PLoS Comput. Biol."},{"key":"13719_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156006","volume":"11","author":"I Riquelme Medina","year":"2016","unstructured":"Riquelme Medina, I. & Lubovac-Pilav, Z. Gene co-expression network analysis for identifying modules and functionally enriched pathways in type 1 diabetes. PLoS ONE 11, e0156006 (2016).","journal-title":"PLoS ONE"},{"key":"13719_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-0381-4-10","volume":"4","author":"GA Pavlopoulos","year":"2011","unstructured":"Pavlopoulos, G. A. et al. Using graph theory to analyze biological networks. BioData Mining 4, 1\u201327 (2011).","journal-title":"BioData Mining"},{"key":"13719_CR96","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"BT Sherman","year":"2009","unstructured":"Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44 (2009).","journal-title":"Nat. Protoc."},{"key":"13719_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","volume":"37","author":"DW Huang","year":"2009","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1\u201313 (2009).","journal-title":"Nucleic Acids Res."},{"key":"13719_CR98","doi-asserted-by":"publisher","first-page":"D649","DOI":"10.1093\/nar\/gkx1132","volume":"46","author":"A Fabregat","year":"2018","unstructured":"Fabregat, A. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 46, D649\u2013D655 (2018).","journal-title":"Nucleic Acids Res."},{"key":"13719_CR99","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb, J. et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929\u20131935 (2006).","journal-title":"Science"},{"key":"13719_CR100","doi-asserted-by":"publisher","first-page":"5286","DOI":"10.7150\/jca.56506","volume":"12","author":"G Li","year":"2021","unstructured":"Li, G. et al. Identification of hub genes and small molecule drugs associated with acquired resistance to Gefitinib in non-small cell lung cancer. J. Cancer 12, 5286\u20135295. https:\/\/doi.org\/10.7150\/jca.56506 (2021).","journal-title":"J. Cancer"},{"key":"13719_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.823566","volume":"9","author":"Y Zheng","year":"2022","unstructured":"Zheng, Y., Meng, X. W. & Yang, J. P. Exploring potential regulatory anesthetic drugs based on RNA binding protein and constructing CESC prognosis model: A study based on TCGA database. Front. Surg. 9, 823566. https:\/\/doi.org\/10.3389\/fsurg.2022.823566 (2022).","journal-title":"Front. Surg."},{"key":"13719_CR102","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.7150\/jca.68568","volume":"13","author":"M Zhao","year":"2022","unstructured":"Zhao, M. et al. Identification and analysis of a prognostic ferroptosis and iron-metabolism signature for esophageal squamous cell carcinoma. J. Cancer 13, 1611\u20131622. https:\/\/doi.org\/10.7150\/jca.68568 (2022).","journal-title":"J. Cancer"},{"key":"13719_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24346","volume":"36","author":"H Yang","year":"2022","unstructured":"Yang, H. & Jiang, Q. A multi-omics-based investigation of the immunological and prognostic impact of necroptosis-related genes in patients with hepatocellular carcinoma. J. Clin. Lab Anal. 36, e24346. https:\/\/doi.org\/10.1002\/jcla.24346 (2022).","journal-title":"J. Clin. Lab Anal."},{"key":"13719_CR104","doi-asserted-by":"publisher","first-page":"14","DOI":"10.21037\/tcr-21-1554","volume":"11","author":"Z Gong","year":"2022","unstructured":"Gong, Z., Li, Q., Li, J., Xie, J. & Wang, W. A novel signature based on autophagy-related lncRNA for prognostic prediction and candidate drugs for lung adenocarcinoma. Transl. Cancer Res. 11, 14\u201328. https:\/\/doi.org\/10.21037\/tcr-21-1554 (2022).","journal-title":"Transl. Cancer Res."},{"key":"13719_CR105","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s12859-020-03691-3","volume":"21","author":"T Zengin","year":"2020","unstructured":"Zengin, T. & \u00d6nal-S\u00fczek, T. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma. BMC Bioinform. 21, 368. https:\/\/doi.org\/10.1186\/s12859-020-03691-3 (2020).","journal-title":"BMC Bioinform."},{"key":"13719_CR106","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/1759-7714.12411","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. Whole genome sequencing analysis of lung adenocarcinoma in Xuanwei, China. Thorac. Cancer 8, 88\u201396. https:\/\/doi.org\/10.1111\/1759-7714.12411 (2017).","journal-title":"Thorac. Cancer"},{"key":"13719_CR107","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1080\/21655979.2022.2037372","volume":"13","author":"DY Li","year":"2022","unstructured":"Li, D. Y., Yue, L. X., Wang, S. G. & Wang, T. X. Quercitrin restrains the growth and invasion of lung adenocarcinoma cells by regulating gap junction protein beta 2. Bioengineered 13, 6126\u20136135. https:\/\/doi.org\/10.1080\/21655979.2022.2037372 (2022).","journal-title":"Bioengineered"},{"key":"13719_CR108","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.lungcan.2014.03.018","volume":"84","author":"SS Han","year":"2014","unstructured":"Han, S. S. et al. RNA sequencing identifies novel markers of non-small cell lung cancer. Lung Cancer 84, 229\u2013235. https:\/\/doi.org\/10.1016\/j.lungcan.2014.03.018 (2014).","journal-title":"Lung Cancer"},{"key":"13719_CR109","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41388-018-0471-1","volume":"38","author":"YP Lin","year":"2019","unstructured":"Lin, Y. P., Wu, J. I., Tseng, C. W., Chen, H. J. & Wang, L. H. Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation. Oncogene 38, 822\u2013837. https:\/\/doi.org\/10.1038\/s41388-018-0471-1 (2019).","journal-title":"Oncogene"},{"key":"13719_CR110","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.2147\/cmar.S163432","volume":"10","author":"K Liu","year":"2018","unstructured":"Liu, K., Jin, M., Xiao, L., Liu, H. & Wei, S. Distinct prognostic values of mRNA expression of glutathione peroxidases in non-small cell lung cancer. Cancer Manag. Res. 10, 2997\u20133005. https:\/\/doi.org\/10.2147\/cmar.S163432 (2018).","journal-title":"Cancer Manag. Res."},{"key":"13719_CR111","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3389\/fgene.2020.00979","volume":"11","author":"S Li","year":"2020","unstructured":"Li, S., Jiang, L., Tang, J., Gao, N. & Guo, F. Kernel fusion method for detecting cancer subtypes via selecting relevant expression data. Front. Genet. 11, 979. https:\/\/doi.org\/10.3389\/fgene.2020.00979 (2020).","journal-title":"Front. Genet."},{"key":"13719_CR112","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.21037\/atm-20-5332","volume":"8","author":"ZW Li","year":"2020","unstructured":"Li, Z. W. et al. Small nucleolar RNA host gene 22 (SNHG22) promotes the progression of esophageal squamous cell carcinoma by miR-429\/SESN3 axis. Ann. Transl. Med. 8, 1007. https:\/\/doi.org\/10.21037\/atm-20-5332 (2020).","journal-title":"Ann. Transl. Med."},{"key":"13719_CR113","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s43141-021-00134-1","volume":"19","author":"R Islam","year":"2021","unstructured":"Islam, R. et al. Identification of molecular biomarkers and pathways of NSCLC: Insights from a systems biomedicine perspective. J. Genet. Eng. Biotechnol. 19, 43. https:\/\/doi.org\/10.1186\/s43141-021-00134-1 (2021).","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"13719_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.802463","volume":"12","author":"W Wang","year":"2021","unstructured":"Wang, W., Bo, H., Liang, Y. & Li, G. LINC00467 Is Upregulated by DNA Copy Number Amplification and Hypomethylation and Shows ceRNA Potential in Lung Adenocarcinoma. Front. Endocrinol. (Lausanne) 12, 802463. https:\/\/doi.org\/10.3389\/fendo.2021.802463 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"13719_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153551","volume":"224","author":"Y Wu","year":"2021","unstructured":"Wu, Y. et al. Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis. Pathol Res Pract 224, 153551. https:\/\/doi.org\/10.1016\/j.prp.2021.153551 (2021).","journal-title":"Pathol Res Pract"},{"key":"13719_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165822","volume":"1866","author":"F Yuan","year":"2020","unstructured":"Yuan, F., Lu, L. & Zou, Q. Analysis of gene expression profiles of lung cancer subtypes with machine learning algorithms. Biochim. Biophys. Acta Mol. Basis Dis. 1866, 165822. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165822 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"13719_CR117","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/853573","volume":"2015","author":"S Zmorzy\u0144ski","year":"2015","unstructured":"Zmorzy\u0144ski, S., \u015awiderska-Ko\u0142acz, G., Koczkodaj, D. & Filip, A. A. Significance of polymorphisms and expression of enzyme-encoding genes related to glutathione in hematopoietic cancers and solid tumors. Biomed. Res. Int. 2015, 853573. https:\/\/doi.org\/10.1155\/2015\/853573 (2015).","journal-title":"Biomed. Res. Int."},{"key":"13719_CR118","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.21037\/atm-20-7936","volume":"9","author":"C Ma","year":"2021","unstructured":"Ma, C., Li, F. & Luo, H. Prognostic and immune implications of a novel ferroptosis-related ten-gene signature in lung adenocarcinoma. Ann. Transl. Med. 9, 1058. https:\/\/doi.org\/10.21037\/atm-20-7936 (2021).","journal-title":"Ann. Transl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13719-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13719-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13719-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:40:20Z","timestamp":1669347620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13719-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["13719"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-13719-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]},"assertion":[{"value":"22 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9417"}}